Hims & Hers (HIMS) has caught a powerful new tailwind, and the market is treating peptides as more than a short-lived headline. The immediate catalyst was the FDA’s decision to hold a July 23-24 meeting of its Pharmacy Compounding Advisory Committee to review whether several peptides should be considered for broader compounding access. The agency’s agenda includes BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax, and Epitalon. Reuters said the FDA’s move helped send Hims shares higher as investors started ...